Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27681
Licensed Products means any product or process which utilizes master cell bank (MCB) or the BC8 monoclonal antibody (MAb).
Licensed Know-How means the MCB, MCB documentation, BC8 MAb manufacturing documentation and all clinical, preclinical and technical data owned or controlled by Licensor related to the BC8 program.
Materials means BC8 MAb and all relevant Investigational New Drug (IND) and Drug Master Files.
The Licensee will build upon previous and ongoing clinical trials, with BC8 (licensed antibody) and eventually develop a clinical trial with Actinium 225.
The Licensor has currently completed Phase I and Phase II of the clinical trial and the Licensee intends to start preparation for a pivotal trial leading to an FDA approval.
Actinium is a radioactive chemical element. Its current applications include a neutron source and an agent for radiation therapy targeting cancer cells in the body.
IPSCIO Record ID: 1010
Licensor has certain rights to a humanized antibody directed against the CD33 antigen and designated by Licensor as HuM195.
HuM195 Antibody means the humanized version of the m195 antibody directed against the CD33 antigen.
Patent No. 5,585,089, Humanized Immunoglobulins
Patent No. 5,693,761, Polynucleotides Encoding Improved Humanized Immunoglobulins
Patent No. 5,693,762, Humanized Immunoglobulins
Patent No. 6,180, 370 Humanized Immunoglobulins and Method of Making the Same
The Licensee secured exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes.
Alpha particles are of considerable interest for radioimmunotherapy applications since their short range in soft tissue is limited to only a few cell diameters. The delivery of such high energy in such a small volume, or high-linear-energy-transfer (LET), makes alpha particles especially well suited for targeting micrometastatic disease and single tumor cells such as leukemia and other blood-borne disease.
IPSCIO Record ID: 27942
For this purpose, the Company entered into a worldwide exclusive license with the Licensor, through which it obtained the right to combine an antibody that specifically binds to lung adenocarcinoma cells with minimal cross reactivity to other tissues with Company's DOS47â„¢ technology.